U.S. Abilify Warning Label Now Includes Compulsive Gambling

The popular antipsychotic Abilify (aripiprazole) received approval from the U.S. Food and Drug Administration (FDA) in 2002 for the treatment of bipolar disorder, schizophrenia and other major depressive disorders. Since then, there have been over 180 reported instances of impulse control problems among Abilify users, including compulsive gambling, shopping, binge [...]

By | September 26th, 2016|Pharma News|

Celexa, Lexapro and the Death of Evidence-Based Medicine

“Oh, what a tangled web we weave. When first we practise to deceive!” From Walter Scott’s epic poem, Marmion This is the story of a drug and an idea, and how, in 2004, the rise of one helped bring about the downfall of the other. The drug is Celexa (generic [...]

Antidepressant Suicide – A Catch-22

What’s wrong with this picture? Company A designs a drug. The company develops it, tests it on animals and ultimately humans, and sends the results of their research—or what they claim are the results—to the Food and Drug Administration (FDA). The FDA approves the drug to be marketed for the treatment [...]

By | July 20th, 2016|Blog, Paxil News, Pharma News, R. Brent Wisner|

Paxil Suicide Case Heads to Trial

No More Stalling of Paxil Suicide Case Chicago, Illinois, January 14, 2016 — A federal judge in Illinois has ruled that a Paxil suicide case alleging GlaxoSmithKline (“GSK”) concealed data linking its antidepressant drug Paxil to suicidal behavior will move forward to trial, bypassing the drug maker’s two motions for summary [...]

By | January 14th, 2016|Blog, Paxil News, Pharma News, Press Releases|

Attorney Tells All: How the U.S. Courts Shield Big Pharma from Liability

It’s not easy to sue Big Pharma.  But, legal firm Baum Hedlund has been doing it for years.  Unfortunately, as pharmaceutical deceit and side-effects grow, it’s getting exponentially more difficult.  After all, using prescription drugs as prescribed is the top killer in the USA. I reached out to attorney Michael Baum to get a [...]

By | November 23rd, 2015|Blog, Michael L. Baum, Pharma News, Press Releases|

Study Data Does Not Support Conclusion that FDA Warnings May Have Led to More Suicides

In a highly publicized article published in the British Medical Journal (BMJ) on June 18, 2014, “Changes in antidepressant use by young people and suicidal behavior after FDA warnings and media coverage: quasi-experimental study,” Dr. Lu and colleagues suggest the FDA’s warnings regarding an increased risk of suicidality in children and [...]

By | November 15th, 2015|Bijan Esfandiari, Pharma News|

Twenty First Century Snake Oil Salesman

A Modern Tale of Perfidy and Comeuppance (A “Fiction” inspired by an article in the September 17, 2015 issue of The Chronicle of Higher Education) Here’s the deal: A medical doctor who acts as a “key opinion leader” (KOL) for Big Pharma puts his or her name on an article [...]

By | September 18th, 2015|Blog, Paxil News, Pharma News, Rons Rants|

Misleading Paxil Study Exposed in New BMJ Study

Study 329, a Poster Child of tainted scientific research, has finally gotten its comeuppance. Study 329 was published in 2001 by over a dozen well-credentialed academics whose names lent credence to the study’s conclusions, but unbeknownst to the medical community and public, the study was ghostwritten by a PR company hired [...]

By | September 18th, 2015|Michael L. Baum, Paxil News, Pharma News|

Federal Judge Denies Dismissal, Sets Cymbalta Withdrawal Trial Dates

We are no longer accepting new Cymbalta withdrawal cases. Los Angeles, California - On Friday, June 19, 2015, Judge Stephen V. Wilson, U.S. District Court for the Central District of California, Los Angeles, denied Cymbalta manufacturer, Eli Lilly and Company’s motions for summary judgment (seeking to dismiss [...]

By | July 23rd, 2015|Cymbalta News, Pharma News|

Criminal Abroad – Home Free Home?

Foreign countries have filed criminal charges against Merck & Co., a major pharmaceutical company, over their HPV vaccine, Gardasil. Some of the charges include failing to properly inform the public of dangerous side effects and fraudulent marketing.While profit remains high in the United States, it’s unlikely that there will be any [...]

By | June 1st, 2015|Pharma News, Rons Rants|